FOLH1 and neoplasm: To improve tumor targeting, PD-CTT1298, a prostate-specific membrane antigen (PSMA)-targeted platform, was developed by conjugating an irreversible PSMA ligand to a generation 4 hydroxyl-terminated PAMAM (PAMAM-G4-OH), enabling precise recognition and drug delivery to prostate cancer cells [233].